MATRIX TABLET OF RASAGILINE MESYLATE: AN APPROACH FOR THE TREATMENT OF PARKINSON DISEASE

Parkinson's disease is a common neurodegenerative disorder that can cause significant disability and decreased quality of life. It is a multidimensional disease and management needs to be holistic, incorporating the patient and family, utilizing a multidisciplinary team and addressing both medical as well as rehabilitation issues from diagnosis to advanced disease. In the present study, sustained release tablets of Rasagiline mesylate is designed using xanthan gum (XG), and hydroxyl propyl methyl cellulose K 100 M (HPMC) as release retarding polymers alone or in combination as Rasagiline is a better alternative and considered as drug of choice for effective treatment of Parkinson's disease with reduced side effects. Tablets were formulated in nine batches by using different ratios of drug and excipients. The drug release profiles of various formulations showed that these were successful in effectively sustaining the drug release from the matrix tablets, as set in objectives. Keywords: Rasagiline mesylate, matrix tablet, in vitro release